Multiple Sclerosis Update: 5 Things to Know

What’s new in MS: teratogenicity of disease-modifying drugs, extended interval natalizumab dosing, a potential biomarker, the “MS hug,” and virtual reality therapy.

from Front page feed http://bit.ly/2XiqWxw